ClinicalTrials.gg
WithdrawnNCT01981811Updated Apr 28, 2015

Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder

A Phase 2 interventional study of Aripiprazole and Ingestible Event Marker (IEM) in Bipolar 1 Disorder, Schizophrenia and Mental Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Withdrawn at 12 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-04-28.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Why this study was withdrawn
The trial was terminated because it was determined that the usability of the MIND1 System in the intended population was necessary before conducting this trial.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 126 studies testing aripiprazole in Schizophrenia — 4 open to participants now, 4 under way, 1 of them phase 3. Aripiprazole · Schizophrenia.

Enrollment
125th of 125
0 · median 130
Started
2014
with 5 others
Phase 2
4 of 126
none open now
Registered
83rd of 126
by date
Lead sponsor
44 of 126
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 126 studies testing aripiprazole in Schizophrenia, this one is the 125th largest by enrollment of the 125 interventional ones that give a count, is one of 6 that started in 2014, is one of 4 in phase 2, and was the 83rd registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 126 studies testing aripiprazole in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About aripiprazole

Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies testing aripiprazole in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate adherence to treatment with, and safety and tolerability of, the medical information device #1 (MIND1) system in subjects with Schizophrenia or Bipolar I Disorder who are currently treated with oral aripiprazole.

Read the detailed description

Poor adherence to medication is a well-recognized problem in psychiatric patients and is a barrier to achieving optimal health. The MIND1 System is being developed to objectively and precisely monitor and measure real-time medication adherence; and to potentially enhance adherence. The MIND1 System includes oral aripiprazole with an embedded ingestible event marker (IEM), a Wearable Sensor, and a computerized device and accessories. This is a trial designed to evaluate adherence to treatment with, and safety and tolerability of, the medical information device #1 (MIND1) system in subjects with schizophrenia or bipolar I disorder. This 12-week, single-arm trial will include male and female subjects 18 to 65years (inclusive) with a current diagnosis of schizophrenia or bipolar I disorder who are currently treated with oral aripiprazole.

03

Conditions studied

  • Bipolar 1 Disorder
  • Schizophrenia
  • Mental Disorder
  • Nervous System Diseases

Keywords

  • OPC-14597 Digital
  • Aripiprazole
  • Medical Information Device #1 System (MIND1)
  • Treatment Adherence
  • Ingestible Event Marker
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females 18 to 65 years of age, inclusive, at time of
  • Schizophrenia: Patients with two or more exacerbations of symptoms in past year leading to an intervention, per investigator's judgment (ie, inpatient psychiatric hospitalization, psychiatric ER visit, admission to partial hospitalization program, crisis residential treatment, etc.). This does not include outpatient adjustment of medication.
  • Bipolar I Disorder: Patients with at least one manic episode or exacerbation of bipolar symptoms in past year resulting in an intervention, per Investigator's judgment (i.e., inpatient psychiatric hospitalization, psychiatric ER visit, admission to partial hospitalization program, crisis residential treatment, etc.) This does not include outpatient adjustment of medication.
  • Current primary Axis-1 diagnosis of bipolar 1 disorder or schizophrenia as defined by criteria
  • Bipolar 1 disorder patients with a total YMRS score of 10 to 25 (inclusive)
  • Schizophrenia patients with a total PANSS score of 60 to 90 (inclusive)
  • Currently prescribed oral Aripiprazole for either bipolar 1 disorder or schizophrenia. No changes in their Aripiprazole dose or regimen 2 weeks before screening.
  • Subjects must be able to tolerate blood draws.
  • If subject is on other psychotropic medications, he/she must be on a stable dose and regimen over the last 2 weeks.

Exclusion criteria

Exclusion Criteria:

  • Subjects with a current Axis I () diagnosis other than bipolar 1 disorder or schizophrenia
  • Subjects with a current Axis II (DSM-IV-TR) diagnosis
  • History of inpatient hospitalization for any psychiatric reason within 2 months before screening
  • Subjects who reside or attend a facility where medication is administered to them
  • Subject has received any product within the last 30 days
  • Allergic, intolerant, or unresponsive to prior treatment with Aripiprazole or other quinolinones
  • History of to antipsychotic agents
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    Aripiprazole and Ingestible Event Marker (IEM)

    All subjects will continue to receive their previously prescribed dose of aripiprazole (10 mg, 15 mg, 20 mg, or 30 mg) through the trial. Subjects will discontinue dosing of the conventional oral aripiprazole tablet and will begin taking MIND1 (aripiprazole embedded with an Ingestible Event Marker) tablet once-daily for 12 weeks.

    Drug: Aripiprazole · Device: Ingestible Event Marker (IEM)

Interventions

06

What researchers measure

Primary outcomes

  1. Medication adherence, as defined by the number of IEM detections reported by the MIND1 System divided by the medication doses prescribed.

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Compliance, defined as the ratio of individual model-predicted exposure (AUC) at Week 12 following administration of oral aripiprazole using the MIND1 System versus the expected exposure

    Time frame: Week 12

Other outcomes

  1. Comparison of the predicted PK exposure (log transformed-area under the plasma concentration-time curve [AUC]) at Week 12 to the predicted PK exposure prior to use of the MIND1 System

    Time frame: Week 12

  2. Change in compliance, defined as the difference in predicted adherence at Week 12 and the predicted adherence before using the MIND1 System

    Time frame: Week 12

  3. Proportion of subjects who achieve greater than 80% compliance post-Week 12 administration of aripiprazole through MIND1

    Time frame: Baseline to Week 12

  4. Severity of illness, defined by the change from Screening/baseline to Week 12 with scores on the CGI-scale, PSP, SLOF, PANSS and YMRS.

    Time frame: Screening/baseline to Week 12

  5. Safety and tolerability: frequency and severity of AEs; frequency of serious AEs; AEs leading to discontinuation; and frequency and severity of unexpected adverse events and unanticipated device adverse events (UDAE)

    Time frame: Baseline to Week 12

07

Study locations

12 sites
  • Cerritos, California 90703, United States
  • Garden Grove, California 92845, United States
  • Long Beach, California 90813, United States
  • National City, California 91950, United States
  • Oceanside, California 92056, United States
  • San Diego, California 92123, United States
  • Washington, District of Columbia 20016, United States
  • Atlanta, Georgia 30308, United States
  • St Louis, Missouri 63118, United States
  • Marlton, New Jersey 08053, United States
  • Dayton, Ohio 45417, United States
  • Irving, Texas 75062, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2014, a primary completion of May 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2013
First posted
Nov 13, 2013
Start
Mar 2014
Primary completionActual
May 2014
CompletionEst.
Dec 2014
Last update
Apr 28, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01981811
Responsible party
Sponsor
First posted
Nov 13, 2013
Start date
Mar 2014
Primary completion
May 2014
Completion
Dec 2014 (estimated)
Last update
Apr 28, 2015

Study contacts

Shashank Rohatagi, PhD
study director · Otsuka Pharmaceutical Development & Commercialization, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aripiprazole

Start the discussion